Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the enrollment of the first patient in a Phase 2b clinical trial of seltorexant (MIN-202) as adjunctive therapy to antidepressants in adult patients with major depressive disorder (MDD) who have responded inadequately to antidepressant therapy.
The primary objectives of this multi-center, double-blind, randomized, parallel group, placebo-controlled, adaptive-dose finding study are:
- to assess the dose-response relationship and antidepressant effects of up to three doses of seltorexant; and
- to assess the safety and tolerability of seltorexant compared to placebo as described in clinicaltrials.gov: NCT03227224.
"An important differentiator of seltorexant is its specificity for the orexin 2 receptor subtype, which is known to have a key role in controlling brain structures and pathways involved in mood and insomnia," said Dr. Remy Luthringer, president and chief executive officer of Minerva. "This trial follows the observed improvements in mood in an earlier study carried out in depressed patients who received seltorexant."
The trial consists of three phases: a screening phase lasting up to four weeks, a six-week double-blind treatment phase and a two-week post-treatment follow-up phase. Approximately 280 patients are planned to be enrolled at more than 85 clinical sites in the U.S., Europe, Russia and Japan.
About Seltorexant (MIN-202)
Seltorexant is a selective orexin 2 receptor antagonist under co-development by Janssen Pharmaceutica NV and Minerva as adjunctive therapy for MDD and for the treatment of insomnia disorder. The orexin system in the brain is involved in the control of several key functions, including metabolism, stress response and wakefulness.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; seltorexant (MIN-202), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to: the timing and results of future clinical milestones with MIN-202 in insomnia and major depressive disorder, including the timing and scope of future clinical trials and results of clinical trials with this compound; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our agreements with Janssen related to seltorexant; our ability to successfully develop and commercialize seltorexant; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether seltorexant will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether the results of future clinical trials of seltorexant, if any, will be consistent with the results of past clinical trials; whether seltorexant will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our co-development agreements; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, filed with the Securities and Exchange Commission on August 3, 2017. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
DealCloud announces global expansion, opening of EMEA Headquarters23.5.2018 08:00 | Pressemelding
LONDON, May 23, 2018 (GLOBE NEWSWIRE) -- DealCloud, a technology leader for deal & relationship management in the private capital markets, announces the opening of its EMEA headquarters in Holborn, London, United Kingdom. With the opening of the regional headquarters in London, DealCloud operates out of 4 offices globally. Supporting a rapidly growing client base in the region, DealCloud now provides implementation services, client support, and account management through a dedicated team based out of the London office. "We work closely with every client to tailor our exceptional technology and capabilities to their specific process," says DealCloud Co-Founder and Chief Revenue Officer Ben Harrison. "We are committed to delivering the best possible results for our clients, and we believe growing our team in London is the best way to do this." "Supporting dozens of clients in EMEA today, and adding new clients every week, we are excited about the impact our office expansion will have wit
Northland Power Announces Retirement of CEO John Brace and Appointment of Mike Crawley as Chief Executive Officer, Effective August 4, 201823.5.2018 01:27 | Pressemelding
TORONTO, May 22, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland") (TSX:NPI) today announced that Chief Executive Officer John Brace will retire on August 4, 2018 after 30 years with the company. Mike Crawley, currently Northland's Executive Vice President, Development has been appointed to the role of Chief Executive Officer, effective August 4, 2018. Mr. Brace and Mr. Crawley will work together to ensure a smooth transition. Mr. Brace will continue to serve as a Director of Northland. John joined Northland in 1988, shortly after the company was founded. He was appointed Chief Executive Officer in 2005. He has steered Northland through many of its projects, initiatives and growth. Under his leadership, the company has grown to its current enterprise value of $12 billion. John was appointed to Northland's Board of Directors on April 4, 2018, and along with Northland's other board members, will stand for re-election at Northland's Annual General Meeting on May 23rd, 2018. Mike
MyoGen: Leaders of an Anabolic Revolution22.5.2018 23:00 | Pressemelding
GUJARAT, India, May 23, 2018 (GLOBE NEWSWIRE) -- Myogen will make you rethink what the human body is capable of. To be an athlete means to partake on a never-ending quest for self-improvement. An obsession to search for a winning edge. Even when we are competing against ourselves, our desire to overcome our physical limitations and achieve new heroic and record setting performances becomes an overwhelming primary focus. Today marks an evolution in what the human body is capable of, with the launch of the MyoGen range of anabolic products. Myogen, the essence of "muscles". MyoGen takes its source from the Greek words "Myo" meaning "Muscle" and "Genesis" meaning "Birth". This implicit historical reference, of the origin of the muscle, displays both the commitment and professionalism of Myogen, and their unwavering focus on peak physical performance. The brightest leader's blaze trails. The Myogen brand is managed by an international team of experts who are committed to making athletes st
Constellation Brands Promotes Jim Sabia to Newly Created Role of Chief Marketing Officer22.5.2018 22:30 | Pressemelding
New role will serve as a member of the company's Executive Management Committee VICTOR, N.Y., May 22, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ) (NYSE:STZ.B), a leading beverage alcohol company, announced today that it has promoted Jim Sabia to the newly created role of Executive Vice President and Chief Marketing Officer, Constellation Brands. In this new role, Sabia will serve as the marketing lead for the company's Beer and Wine & Spirits Divisions, responsible for all aspects of marketing across Constellation's entire beverage alcohol portfolio. Sabia will serve as a member of the company's Executive Management Committee and report directly to Bill Newlands, President and Chief Operating Officer. "Our company's core mission is to build brands consumers love and Jim has been a driving force behind the success of our beer brands over the years," said Newlands. "It is critically important that the voice of the consumer and brand-building principles have strong repr
Algeco Announces First Quarter 2018 Financial Results Conference Call22.5.2018 17:52 | Pressemelding
BALTIMORE, May 22, 2018 (GLOBE NEWSWIRE) -- Algeco Investments B.V. (together with its subsidiaries, "Algeco"), the leading global business services provider of modular space, secure portable storage solutions and remote workforce accommodations, today announced that it will hold its first quarter 2018 financial results conference call on Tuesday, June 5, 2018 at 10:00 a.m., Eastern Time. To access the call, please dial (847) 585-4422 or (888) 424-8151 (US toll free) and enter participant PIN code 9192211# approximately ten minutes prior to the start of the call. You will be placed on hold until the event begins. The conference call will also be broadcast over the internet with an accompanying slide presentation. To join the web conference, go to http://web.meetme.net/r.aspx?p=2&a=UTzMrdwdRriEIu. Please enter your name, email address and company to join the call. The customer service team can be reached at any time by pressing *0 on your telephone keypad. On Wednesday, May 30, 2018 at
Hitachi Named a Visionary in Inaugural Gartner Magic Quadrant for Industrial IoT Platforms22.5.2018 15:00 | Pressemelding
Hitachi Positioned in Visionaries Quadrant for Completeness of Vision and Ability To Execute TOKYO and SANTA CLARA, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- Hitachi, Ltd. (TSE:6501) and Hitachi Vantara, today announced that Hitachi has been positioned in the Visionaries quadrant of the inaugural Gartner Magic Quadrant for Industrial IoT Platforms1based on Gartner, Inc.'s evaluation of the company, which included Hitachi's Lumada IoT platform. Gartner describes the market for IIoT platforms as "a set of integrated software capabilities. These capabilities span efforts to improve asset management decision-making, as well as operational visibility and control for plants, depots, infrastructure and equipment within asset-intensive industries." In the report, Gartner predicts: "By 2020, on-premises Internet of Things (IoT) platforms coupled with edge computing will account for up to 60% of industrial IoT (IIoT) analytics, up from less than 10% today." The report also notes: "Gartner believe
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom